RE:------WHO IN THEIR RIGHT MIND---
by @nasdaq on 28 Jan 2020, 10:15 Vaxil Announces Financing Update NESS-ZIONA, Israel, Jan. 28, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (Vaxil or the Company) (TSX VENTURE: VXL), an innovative immunotherapy biotech focused on cancer and infectious diseases, announces that the Company was not able to close the previously announced non-brokered private placement of up to 18,750,000 common shares at a price of CDN$0.04 per share for gross proceeds of up to CDN$750,000. NESS-ZIONA, Israel, Feb. 13, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (Vaxil or the Company) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce that it has completed in silico analyses and believes that it has successfully identified a corona virus (COVID-19) vaccine candidate (Vaccine Candidate). The Vaccine Candidate is based on unique and patent protected signal peptide technology, utilizing Vaxils proprietary VaxHit bioinformatics platform. The Vaccine Candidates design is also based on successful in vivo experiments testing a tuberculosis signal peptide vaccine. Not for distribution by US newswire or in United States NESS-ZIONA, Israel, June 29, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (Vaxil or the Company) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, would like to provide an update on its previously announced brokered private placement of up to 58,823,530 units of the Company with minimum gross proceeds of $2,000,000 (the "Offering"), with M Partners Inc. as Lead Agent. The Offering remains in progress and the closing date has been extended and is expected to occur on or about July 17, 2020. Further details of the Offering are included in the Companys press release from May 26, 2020.